1. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
- Author
-
Abeysekera I, Thomas J, Georgiadis TM, Berman AG, Hammond MA, Dria KJ, Wallace JM, and Roper RJ
- Subjects
- Absorptiometry, Photon, Animals, Bone and Bones abnormalities, Catechin chemistry, Catechin pharmacology, Dietary Supplements, Disease Models, Animal, Down Syndrome diet therapy, Female, Femur diagnostic imaging, Femur drug effects, Femur physiopathology, Male, Mice, Inbred C57BL, Mice, Mutant Strains, X-Ray Microtomography, Bone and Bones drug effects, Catechin analogs & derivatives, Down Syndrome physiopathology
- Abstract
Scope: Down syndrome (DS), caused by trisomy of human chromosome 21 (Hsa21), is characterized by a spectrum of phenotypes including skeletal abnormalities. The Ts65Dn DS mouse model exhibits similar skeletal phenotypes as humans with DS. DYRK1A, a kinase encoded on Hsa21, has been linked to deficiencies in bone homeostasis in DS mice and individuals with DS. Treatment with Epigallocatechin-3-gallate (EGCG), a known inhibitor of Dyrk1a, improves some skeletal abnormalities associated with DS in mice. EGCG supplements are widely available but the effectiveness of different EGCG-containing supplements has not been well studied., Methods and Results: Six commercially available supplements containing EGCG were analyzed, and two of these supplements were compared with pure EGCG for their impact on skeletal deficits in a DS mouse model. The results demonstrate differential effects of commercial supplements on correcting skeletal abnormalities in Ts65Dn mice. Different EGCG-containing supplements display differences in degradation, polyphenol content, and effects on trisomic bone., Conclusion: This work suggests that the dose of EGCG and composition of EGCG-containing supplements may be important in correcting skeletal deficits associated with DS. Careful analyses of these parameters may lead to a better understanding of how to improve skeletal and other deficits that impair individuals with DS., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2016
- Full Text
- View/download PDF